Latest Information

Radiofrequency Ablation, Partial Nephrectomy for RCC Offer Similar Long-Term Outcomes

January 11, 2012
In appropriately selected patients, radiofrequency ablation (RFA) is an effective minimally invasive treatment for cT1a renal cell carcinoma (RCC) that offers long-term oncologic outcomes comparable to nephron-sparing surgery, data show.

Ultrasound Not Inferior for Sizing Renal Masses

January 06, 2012
Ultrasound imaging works as well as computed tomography (CT) and magnetic resonance imaging (MRI) for evaluating renal mass size, a new study suggests.

Aveo Announces Kidney Cancer Drug Tivozanib Meets Late-Stage Goal

January 4, 2012
“The drug helped patients with advanced renal cell carcinoma live for 11.9 months without their disease progressing in a late-stage study, compared with 9.1 months for those on Nexavar [sorafenib].”

ICUD/EAU consensus statement on mRCC

The International Consultation on Urological Diseases and the European Association of Urology have published a consensus statement on the management of mRCC (Patard et al. Eur Urol 2011; 60: 684-690; www.ncbi.nlm.nih.gov/pubmed/21704448).

The groups’ recommendations are in accord with other published guidelines. The recommended first-line treatments for patients with a favourable or intermediate prognosis are sunitinib or bevacizumab/interferon-alfa. Temsirolimus is recommended first-line for poor-risk patients. Sunitinib or sorafenib is recommended as second-therapy in patients who have failed prior cytokine therapy.

Newly-added treatment options are pazopanib as a first-line treatment or as second-therapy after prior cytokines. ICUD/EAU now recommends everolimus for second-line treatment in patients who are refractory to VEGF-targeted therapy.

Filed Under: Uncategorized